OPU
ALXN

Omni Partners US’s Alexion Pharmaceuticals ALXN Stock Holding History

Omni Partners US’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,283,115
Closed -$326M – 291
2021
Q2 		$326M Buy
+1,283,115
New +$220M 14.36% 1

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Omni Partners US's ALXN Position: Q3 2021 in Review

Omni Partners US sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,283,115 shares — an estimated $326M sold.

Omni Partners US first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $326M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Omni Partners US reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Omni Partners US sold 1,283,115 Alexion Pharmaceuticals shares in Q3 2021, an estimated $326M.
  • Omni Partners US first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Omni Partners US's Alexion Pharmaceuticals position peaked at $326M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.